JP2020531463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531463A5 JP2020531463A5 JP2020508985A JP2020508985A JP2020531463A5 JP 2020531463 A5 JP2020531463 A5 JP 2020531463A5 JP 2020508985 A JP2020508985 A JP 2020508985A JP 2020508985 A JP2020508985 A JP 2020508985A JP 2020531463 A5 JP2020531463 A5 JP 2020531463A5
- Authority
- JP
- Japan
- Prior art keywords
- citrate
- cancer
- pharmaceutical composition
- composition according
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- NWYDRHSNEATNRI-SQQVDAMQSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid (16E)-14-methyl-20-oxa-5,7,14,27-tetrazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.N=1C2=CC=NC=1NC(C=1)=CC=CC=1CN(C)C\C=C\CCOC1=CC=CC2=C1 NWYDRHSNEATNRI-SQQVDAMQSA-N 0.000 claims description 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547157P | 2017-08-18 | 2017-08-18 | |
| US62/547,157 | 2017-08-18 | ||
| PCT/US2018/000264 WO2019035985A1 (en) | 2017-08-18 | 2018-08-17 | POLYMORPHIC FORM OF TG02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531463A JP2020531463A (ja) | 2020-11-05 |
| JP2020531463A5 true JP2020531463A5 (enExample) | 2021-09-30 |
| JP7250764B2 JP7250764B2 (ja) | 2023-04-03 |
Family
ID=65359869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508985A Active JP7250764B2 (ja) | 2017-08-18 | 2018-08-17 | Ｔｇ０２の多形形態 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10544162B2 (enExample) |
| EP (2) | EP3668876B1 (enExample) |
| JP (1) | JP7250764B2 (enExample) |
| KR (1) | KR102758037B1 (enExample) |
| CN (1) | CN111372934B (enExample) |
| AU (1) | AU2018317865B2 (enExample) |
| CA (1) | CA3073270A1 (enExample) |
| ES (1) | ES2977589T3 (enExample) |
| IL (1) | IL272697B2 (enExample) |
| MX (1) | MX2020001875A (enExample) |
| RU (1) | RU2020111019A (enExample) |
| SG (1) | SG11202001441WA (enExample) |
| TW (1) | TWI785098B (enExample) |
| WO (1) | WO2019035985A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230020549A (ko) | 2016-03-24 | 2023-02-10 | 코테라 바이오사이언스 인코포레이티드 | Tg02를 사용한 암의 치료 |
| TWI785098B (zh) | 2017-08-18 | 2022-12-01 | 開曼群島商科賽睿生命科學公司 | Tg02之多晶型 |
| WO2020219606A1 (en) | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
| CN110664760B (zh) * | 2019-10-28 | 2020-10-23 | 浙江大学 | 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用 |
| WO2024031406A1 (en) * | 2022-08-10 | 2024-02-15 | Xiang Li | Idh mutations as biomarkers for zotiraciclib therapy |
| CN115429793A (zh) * | 2022-08-15 | 2022-12-06 | 复旦大学附属中山医院 | 一种化合物在制备治疗肝细胞癌药物中的应用 |
| CN115305251B (zh) * | 2022-08-30 | 2023-06-27 | 中国农业科学院北京畜牧兽医研究所 | Ap2-mybl2分子模块在调控原花色素生物合成中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001011A1 (en) | 1980-09-24 | 1982-04-01 | Corp Cetus | Diagnostic method and probe |
| DE3381518D1 (de) | 1982-01-22 | 1990-06-07 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| EP1472265A4 (en) | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA INTERFERENCE MEDIA INHIBITION OF THE EXPRESSION OF THE POLYCOMB GROUP EZH2 PROTEIN GENE USING A SHORT INTERFERING NUCLEIC ACID (SINA) |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| CA2598239C (en) | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| TWI525096B (zh) | 2005-11-16 | 2016-03-11 | Ｃｔｉ生技製藥有限公司 | 氧連接之嘧啶衍生物 |
| KR101511074B1 (ko) | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| GB0806652D0 (en) | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP2418955A4 (en) | 2009-04-15 | 2012-11-21 | Poniard Pharmaceuticals Inc | ORBIOTIC ANTICANCER THERAPY BASED ON HIGH BIODISIBILITY PICOPLATIN |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| EA027622B1 (ru) * | 2010-02-05 | 2017-08-31 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Твердофазные формы макроциклических ингибиторов киназы |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| CA2795765C (en) | 2010-04-06 | 2020-07-07 | Fred Hutchinson Cancer Research Center | Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2765155C2 (ru) | 2010-09-10 | 2022-01-26 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| EP2760452A4 (en) | 2011-09-30 | 2015-04-01 | Glaxosmithkline Llc | METHODS OF TREATING CANCER |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| EP3536314A1 (en) | 2012-03-12 | 2019-09-11 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| AU2013331368A1 (en) | 2012-10-15 | 2015-04-30 | Epizyme, Inc. | Methods of treating cancer |
| HUE040434T2 (hu) | 2013-02-21 | 2019-03-28 | Pfizer | Szelektív CDK4/6 inhibitor szilárd alakjai |
| MY210104A (en) | 2013-03-15 | 2025-08-27 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
| KR20210143932A (ko) | 2013-09-11 | 2021-11-29 | 메디뮨 리미티드 | 종양 치료용 항-ｂ7-ｈ1 항체 |
| AU2015225867B2 (en) | 2014-03-07 | 2020-02-06 | University Health Network | Methods and compositions for modifying the immune response |
| EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| EA036325B1 (ru) | 2014-03-14 | 2020-10-27 | Аджиос Фармасьютикалз, Инк. | Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1 |
| KR20230020549A (ko) | 2016-03-24 | 2023-02-10 | 코테라 바이오사이언스 인코포레이티드 | Tg02를 사용한 암의 치료 |
| TWI785098B (zh) | 2017-08-18 | 2022-12-01 | 開曼群島商科賽睿生命科學公司 | Tg02之多晶型 |
-
2018
- 2018-08-17 TW TW107128900A patent/TWI785098B/zh active
- 2018-08-17 CA CA3073270A patent/CA3073270A1/en active Pending
- 2018-08-17 CN CN201880065266.0A patent/CN111372934B/zh active Active
- 2018-08-17 SG SG11202001441WA patent/SG11202001441WA/en unknown
- 2018-08-17 JP JP2020508985A patent/JP7250764B2/ja active Active
- 2018-08-17 RU RU2020111019A patent/RU2020111019A/ru unknown
- 2018-08-17 EP EP18846214.7A patent/EP3668876B1/en active Active
- 2018-08-17 WO PCT/US2018/000264 patent/WO2019035985A1/en not_active Ceased
- 2018-08-17 AU AU2018317865A patent/AU2018317865B2/en active Active
- 2018-08-17 ES ES18846214T patent/ES2977589T3/es active Active
- 2018-08-17 KR KR1020207007701A patent/KR102758037B1/ko active Active
- 2018-08-17 EP EP24152903.1A patent/EP4364741A3/en active Pending
- 2018-08-17 US US15/998,872 patent/US10544162B2/en active Active
- 2018-08-17 MX MX2020001875A patent/MX2020001875A/es unknown
- 2018-08-17 IL IL272697A patent/IL272697B2/en unknown
-
2020
- 2020-01-24 US US16/751,969 patent/US12043630B2/en active Active
-
2023
- 2023-12-06 US US18/530,765 patent/US20240254142A1/en active Pending
- 2023-12-06 US US18/530,745 patent/US20240254141A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531463A5 (enExample) | ||
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| JP6147799B2 (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| JP2019077692A (ja) | 癌および骨癌疼痛の治療方法 | |
| JP2019510832A5 (enExample) | ||
| JP2012533570A5 (enExample) | ||
| JP2020500862A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| JP2016528162A (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| CN111012785B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途 | |
| JP2015511609A5 (enExample) | ||
| JP2008521928A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2012522837A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2012509279A5 (enExample) | ||
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| TW201040143A (en) | Treatment regimen utilizing neratinib for breast cancer | |
| JP2009506054A5 (enExample) | ||
| WO2012000421A1 (zh) | 棉酚衍生物在制备抗肿瘤药物中的应用 | |
| JP2012528186A5 (enExample) | ||
| CN114423762A (zh) | 大环类衍生物及其制备方法和用途 | |
| JP2018511642A5 (enExample) | ||
| JP2017530143A5 (enExample) | ||
| JP2011500841A5 (enExample) |